PATH241227C13000
- 0.23
- 0.000.00%
UiPath Newsroom
Needham Maintains UiPath(PATH.US) With Hold Rating
UiPath Maintains Hold Rating Amid Mixed Demand Signals and Regional Disparities
UiPath Analyst Ratings
UiPath Initiated at Sell by UBS
UiPath Analyst Ratings
UBS Initiates UiPath(PATH.US) With Sell Rating, Announces Target Price $14
A Quick Look at Today's Ratings for UiPath(PATH.US), With a Forecast Between $15 to $18
UiPath Price Target Raised to $16.00/Share From $15.00 by Barclays
UiPath Price Target Raised to $16.00/Share From $15.00 by Morgan Stanley
UiPath Price Target Raised to $16.00/Share From $15.00 by BMO Capital
UiPath Price Target Maintained With a $16.00/Share by RBC Capital
UiPath Is Maintained at Overweight by JP Morgan
JP Morgan Maintains Overweight on UiPath, Raises Price Target to $18
A Quick Look at Today's Ratings for UiPath(PATH.US), With a Forecast Between $16 to $19
UiPath's Growth Potential and Favorable Valuation Supports Buy Rating
UiPath's Modest ARR Growth and Challenges: Hold Rating Maintained Amid Stagnant Customer Acquisition and Execution Uncertainties
UiPath Analyst Ratings
Analysts Conflicted on These Technology Names: UiPath (PATH), Apple (AAPL) and Cricut Inc (CRCT)
UiPath's Steady Performance and Operational Improvements Lead to Hold Rating Amid Uncertain Competitive Landscape
UiPath (PATH) Q3 Pre-Earnings: Analysts Forecast 42% Decline in Earnings